Research Analysts Set Expectations for SANA Q3 Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Sana Biotechnology to ($0.15) per share, reflecting increased optimism from a previous estimate of ($0.18).
• Sana Biotechnology has a current market capitalization of $747.46 million, with shares trading at approximately $3.32, up by 6.6% recently.
• Six research analysts rated Sana Biotechnology with a "Buy" rating, with an average target price of $8.00, while HC Wainwright set a price objective of $11.00.

Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) - Equities research analysts at HC Wainwright boosted their Q3 2025 earnings estimates for shares of Sana Biotechnology in a report issued on Tuesday, August 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.15) per share for the quarter, up from their previous estimate of ($0.18). HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Sana Biotechnology's current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology's Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.56) EPS and FY2029 earnings at ($0.41) EPS.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04.

SANA has been the topic of a number of other reports. Morgan Stanley assumed coverage on shares of Sana Biotechnology in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 target price on the stock. JMP Securities restated a "market outperform" rating and issued a $5.00 target price on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Sana Biotechnology currently has an average rating of "Buy" and an average target price of $8.00.

Sana Biotechnology Stock Down 2.5%

Sana Biotechnology stock traded down $0.0850 during midday trading on Thursday, reaching $3.3150. The stock had a trading volume of 1,924,153 shares, compared to its average volume of 5,944,729. The firm has a market cap of $788.34 million, a price-to-earnings ratio of -3.11 and a beta of 1.90. The company has a fifty day moving average of $3.57 and a 200 day moving average of $2.68. Sana Biotechnology has a 52-week low of $1.26 and a 52-week high of $7.30.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Boxer Capital Management LLC acquired a new stake in shares of Sana Biotechnology in the fourth quarter valued at about $2,518,000. Corient Private Wealth LLC boosted its position in Sana Biotechnology by 264.7% during the second quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company's stock worth $3,101,000 after acquiring an additional 824,505 shares during the last quarter. AQR Capital Management LLC boosted its position in Sana Biotechnology by 136.7% during the second quarter. AQR Capital Management LLC now owns 1,356,363 shares of the company's stock worth $3,703,000 after acquiring an additional 783,217 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Sana Biotechnology during the second quarter worth about $1,916,000. Finally, Millennium Management LLC boosted its holdings in Sana Biotechnology by 604.8% in the 4th quarter. Millennium Management LLC now owns 728,901 shares of the company's stock valued at $1,188,000 after purchasing an additional 625,481 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company's stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.